A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens

Expert Opin Drug Metab Toxicol. 2023 Feb;19(2):53-56. doi: 10.1080/17425255.2023.2190883. Epub 2023 Mar 23.

Authors

Rachel Chevalier^{1

2}, Thomas Attard^{1

2}, Sara L Van Driest³, Valentina Shakhnovich^{1

2}

Affiliations

¹ University of Missouri School of Medicine, Kansas, MO, USA.
² Children's Mercy Kansas City, Division of Gastroenterology, Hepatology and Nutrition, Kansas City, MO, USA.
³ Department of Pediatrics, Center for Pediatric Precision Medicine, Nashville, TN, USA.

PMID: 36919492
DOI: 10.1080/17425255.2023.2190883

No abstract available

Keywords: CYP2C19; Proton pump inhibitors; adverse events; gastroesophageal reflux disease (GERD); interstitial nephritis; pharmacogenetics.

Publication types

Editorial
Comment

MeSH terms

Cytochrome P-450 CYP2C19 / genetics
Genotype
Humans
Pharmacogenetics*
Proton Pump Inhibitors* / adverse effects

Substances

Proton Pump Inhibitors
Cytochrome P-450 CYP2C19
CYP2C19 protein, human